Evolver Fund II has acquired a controlling interest in Repolar Pharmaceuticals, aiming to boost its growth in the Nordic and international wound care markets.

Target Company Overview

On August 29, 2024, Evolver Fund II successfully acquired a controlling interest in Repolar Pharmaceuticals Oy, a Finnish family-owned company. Established in 2006 by the Sipponen family, comprised of medical doctors, Repolar specializes in the research, development, manufacturing, and marketing of resin-based treatment products for both humans and animals. The company's product lineup is categorized as self-care products, primarily focusing on wound treatment and skincare tailored for both home and professional use. A notable product from Repolar is Abilar® wound salve, which is widely available at pharmacies across Finland.

Repolar Pharmaceuticals is headquartered in Espoo, Finland, and reported a turnover of €3.2 million in 2023. Founders Arno Sipponen and Lauri Sipponen, alongside Janne Jokinen, remain significant shareholders in the company, with CEO Paavo Heikkinen also retaining a stake and continuing to lead the business post-investment.

Industry Overview in Finland

The Finnish healthcare and pharmaceutical market is characterized by innovation and a strong emphasis on research and development. Finland’s health sector has gained international recognition for its high standards and ad